Phase I Study of TTI-101, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients With Advanced Cancers
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2018
Price : $35 *
At a glance
- Drugs C188-9 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors StemMed; Tvardi Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 22 Dec 2017 Status changed from not yet recruiting to recruiting.
- 10 Oct 2017 Planned initiation date changed from 1 Jul 2017 to 1 Nov 2017.